Sulfateq

Executive Summary

Sulfateq BV is a privately-held Dutch biotechnology company pioneering a novel class of small molecules (SUL compounds) targeting mitochondrial dysfunction. Inspired by natural mechanisms of mitochondrial stress resistance, including those observed during hibernation, Sulfateq’s compounds have a unique mechanism of action that has the potential to transform the standard of care for a broad range of diseases—from metabolic and neurodegenerative disorders to ischemia-reperfusion injury. Founded in 2018 and based in Leiden, the company has leveraged its proprietary compound library to generate promising preclinical data, positioning itself as an innovative player in the mitochondrial therapeutics space. Despite being at an early stage with no disclosed financials or public pipeline, Sulfateq’s science is grounded in a compelling biological rationale, which could attract partnership or funding interest as it progresses toward clinical development. The company’s future hinges on advancing its lead candidates through preclinical validation and securing the necessary capital to reach first-in-human studies. As a private entity with limited public disclosures, the timeline and probability of success for upcoming milestones are uncertain, but the field of mitochondrial medicine is gaining traction. Key catalysts could include the announcement of a Series A financing round, presentation of in vivo efficacy data at a major conference, or initiation of IND-enabling studies. Given the early stage, conviction is moderate; however, the novelty of the approach and the breadth of potential indications offer upside if the science translates.

Upcoming Catalysts (preview)

• H2 2026Series A financing round45% success
• Q4 2026In vivo efficacy data presentation at a scientific conference50% success
• 2027Initiation of IND-enabling studies for lead candidate30% success